MOLECULAR DIAGNOSTIC TEST FOR LUNG CANCER

摘要

Methods and compositions are provided for the identification of a molecular diagnostic test for lung cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with NSCLC are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.

主权项

1. A method of predicting responsiveness of an individual having non-small cell lung cancer (NSCLC) to treatment with a DNA-damaging therapeutic agent comprising:
a. measuring expression levels of one or more biomarkers in a test cancer sample obtained from the individual, wherein the one or more biomarkers are selected from Table 2B, 1A, 1B, 1C, 2A, 3A, 3B, and/or 3C; b. deriving a test score that captures the expression levels; c. providing a threshold score comprising information correlating the test score and responsiveness; d. and comparing the test score to the threshold score; wherein responsiveness is predicted when the test score exceeds the threshold score and/or wherein a lack of responsiveness is predicted when the test score does not exceed the threshold score.